Novel insights into combination therapy in metastatic castration-resistant prostate cancer
Final survival data from the TALAPRO-2 study support the use of a PARP inhibitor plus an androgen receptor pathway inhibitor
Cancer Control Principles
Hypofractionation may help reduce the impact of radiotherapy on the environment
Recent research suggests a substantial reduction in greenhouse gas emissions with de-escalation per cancer patient
Novel data continue to support the use of perioperative durvalumab with neoadjuvant chemotherapy in bladder cancer
Additional analysis from the NIAGARA study were presented
Final analysis reports a lack of overall survival benefit with datopotamab deruxtecan in HR+/HER2– breast cancer compared to chemotherapy
However, secondary endpoints of the TROPION-Breast01 continue to support a potential benefit of the antibody-drug conjugate in previously treated patients
Clinical benefits shown with pembrolizumab plus chemotherapy regardless bevacizumab use in advanced or recurrent cervical cancer
Findings are from an exploratory subgroup analysis of the KEYNOTE-826
Neoadjuvant pembrolizumab plus chemotherapy increases pathological complete response in high-risk early breast cancer
Updated results from the KEYNOTE-756 trial show benefits of the chemoimmunotherapy across subgroups of patients with ER+/HER2− breast cancer
Tiragolumab plus atezolizumab failed to improve overall survival in advanced non-squamous NSCLC
The reduced efficacy compared to the first-line standard of care led to the termination of the SKYSCRAPER-06 study
Sacituzumab govitecan failed to improve overall survival in pre-treated urothelial carcinoma
Despite being active in this disease setting, the antibody-drug conjugate was associated to high rates of neutropenic complications
Mixed results for additional immunotherapy to standard care in stage III NSCLC
Different combinations of immunotherapy agent and radiotherapy or chemoradiotherapy were tested in some patient populations in two studies
Targeting claudins in pancreatic adenocarcinoma is promising, early-phase findings suggest
Study confirms favourable safety profiles and encouraging efficacy of an anti-claudin 18.2 antibody-drug conjugate